Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; none of the 4 sources its claims cite is checked for support yet.

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study

Open access
· 2015 · The Lancet Diabetes & Endocrinology

Abstract

Background Effective prevention is needed to combat the worldwide epidemic of type 2 diabetes. We investigated the long-term extent of beneficial effects of lifestyle intervention and metformin on diabetes prevention, originally shown during the 3-year Diabetes Prevention Program (DPP), and assessed whether these interventions reduced diabetes-associated microvascular complications. Methods The DPP (1996-2001) was a randomised trial comparing an intensive lifestyle intervention or masked metformin with placebo in a cohort selected to be at very high risk of developing diabetes. All participants were offered lifestyle training at the end of the DPP. 2776 (88%) of the surviving DPP cohort were followed up in the DPP Outcomes Study (DPPOS, Sept 1, 2002, to Jan 2, 2014) and analysed by intention to treat on the basis of their original DPP assignment. During DPPOS, the original lifestyle intervention group was offered lifestyle reinforcement semi-annually and the metformin group received unmasked metformin. The primary outcomes were the development of diabetes and the prevalence of microvascular disease. For the assessment of microvascular disease, we used an aggregate microvascular outcome, composed of nephropathy, retinopathy, and neuropathy. Findings During a mean follow-up of 15 years, diabetes incidence was reduced by 27% in the lifestyle intervention group (hazard ratio 0·73, 95% CI 0·65-0·83; p<0·0001) and by 18% in the metformin group (0·82, 0·72-0·93; p=0·001), compared with the placebo group, with declining between-group differences over time. At year 15, the cumulative incidences of diabetes were 55% in the lifestyle group, 56% in the metformin group, and 62% in the placebo group. The prevalences at the end of the study of the aggregate microvascular outcome were not significantly different between the treatment groups in the total cohort (placebo 12·4%, 95% CI 11·1-13·8; metformin 13·0%, 11·7-14·5; lifestyle intervention 11·3%, 10·1-12·7). However, in women (n=1887) the lifestyle intervention was associated with a lower prevalence (8·7%, 95% CI 7·4-10·2) than in the placebo (11·0%, 9·6-12·6) and metformin (11·2%, 9·7-12·9) groups, with reductions in the lifestyle intervention group of 21% (p=0·03) compared with placebo and 22% (p=0·02) compared with metformin. Compared with participants who developed diabetes, those who did not develop diabetes had a 28% lower prevalence of microvascular complications (relative risk 0·72, 95% CI 0·63-0·83; p<0·0001). Interpretation Lifestyle intervention or metformin significantly reduced diabetes development over 15 years. There were no overall differences in the aggregate microvascular outcome between treatment groups; however, those who did not develop diabetes had a lower prevalence of microvascular complications than those who did develop diabetes. This result supports the importance of diabetes prevention. Funding National Institute of Diabetes and Digestive and Kidney Diseases.

Overview

CoChat Summary

TL;DR

In the DPP Outcomes Study, lifestyle intervention and metformin each reduced diabetes incidence over a mean 15 years compared with placebo, but neither reduced aggregate microvascular complications in the total cohort. Lifestyle intervention was associated with lower microvascular disease in women and in participants who remained free of diabetes.

Key findings

  • Over an average 15 years, diabetes incidence was lower by 27% with lifestyle intervention (HR 0.73 [95% CI 0.65–0.83]) and 18% with metformin (HR 0.82 [0.72–0.93]) versus placebo. Cumulative diabetes incidence by year 15 was 560 (62%) in placebo, 499 (56%) in metformin, and 480 (55%) in lifestyle.
  • Aggregate microvascular outcome prevalence at DPPOS-end did not differ significantly among the three treatment groups overall. In women, lifestyle intervention reduced microvascular disease by 21% versus placebo (RR 0.79) and 22% versus metformin (RR 0.78); metformin did not reduce microvascular disease in either sex.
  • Participants who did not develop diabetes had a 28% lower prevalence of the aggregate microvascular outcome than those who developed diabetes (RR 0.72) across all treatment groups combined.
  • In a post-hoc analysis among participants whose latest HbA1c was ≥6.5% (about 25% of the cohort), lifestyle showed significant reductions versus placebo in aggregate microvascular outcome (RR 0.59), retinopathy (RR 0.51), and neuropathy (RR 0.39); no significant metformin–placebo differences were seen.

Methods

  • DPP was a randomized controlled trial at 27 US centers comparing placebo, metformin 850 mg twice daily, and intensive lifestyle intervention (16-session curriculum targeting 7% weight loss and 150 minutes/week moderate activity). DPPOS followed 2776 (88%) of 3149 surviving DPP participants from all three arms, regardless of diabetes status, for a total mean follow-up of 15 years.
  • Diabetes was diagnosed by 75 g OGTT annually and FPG every 6 months, with confirmation. The aggregate microvascular outcome included nephropathy, retinopathy, and neuropathy, measured during the final DPPOS year; analyses were intention-to-treat.
  • Time to diabetes was compared with modified product-limit life-table distributions and log-rank tests. Aggregate microvascular outcomes were analyzed with GEE global tests; pairwise comparisons used Bonferroni-adjusted α=0.025. Analyses used SAS version 9.3.

Limitations

  • Stated: therapeutic cross-over occurred because all three groups were offered group lifestyle intervention during the one-year bridge after DPP; lifestyle intervention after the first 24 weeks and during DPPOS was less intensive, likely contributing to weight regain; metformin use by lifestyle and placebo participants may have diminished relative metformin effects.
  • Stated: the aggregate microvascular outcome combined three outcomes, one of which—neuropathy measured by monofilament—was more subjective and less sensitive for early neuropathy. Generalizability of a clinical trial with selected populations and protocol-driven interventions in academic centers may also be questioned.
  • Stated/evident: the lack of an overall treatment effect on microvascular outcomes despite reduced diabetes development may be owing to limited power, the sex disparity in effects, or small separation in HbA1c among groups. Missing data were assumed missing at random, with 87% completion of microvascular components.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(15)00291-0

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Diabetes Prevention Program Outcomes Study consort diagram
Figure 1 Diabetes Prevention Program Outcomes Study consort diagramCC BY-NC-ND · PubMed Central
Figure 2 Cumulative incidence of diabetes by treatment group among the 2776 DPPOS participants. The DPP and DPPOS periods, and the overlap between them, are indicated. Over the entire study, the incidence rates for participants were 7.0%, 5.7% and 5.2% per year for placebo, metformin and lifestyle, respectively, 27% and 18% lower for lifestyle and metformin vs. placebo, respectively (p<0.0001 and p= 0.001). The difference between lifestyle and metformin was not significant (p=0.10). The number at risk at each time point is listed by treatment group.
Figure 2 Cumulative incidence of diabetes by treatment group among the 2776 DPPOS participants. The DPP and DPPOS periods, and the overlap between them, are indicated. Over the entire study, the incidence rates for participants were 7.0%, 5.7% and 5.2% per year for placebo, metformin and lifestyle, respectively, 27% and 18% lower for lifestyle and metformin vs. placebo, respectively (p<0.0001 and p= 0.001). The difference between lifestyle and metformin was not significant (p=0.10). The number at risk at each time point is listed by treatment group.CC BY-NC-ND · PubMed Central
Figure 3 Prevalence of aggregate microvascular complication and individual microvascular components by DPPOS end (2012–2013). Placebo (red solid), metformin (blue dotted pattern), lifestyle (green diagonal stripes). 3A. By treatment group. None of the treatment group differences achieved statistical significance for the aggregate or the microvascular components. The aggregate microvascular is expressed as the average prevalence among the 3 components of nephropathy, retinopathy and neuropathy. 3B. By pre-specified subgroups according to sex and diabetes status. Prevalence was greater in men than in women in each of the three treatment groups. In women, the prevalence of the aggregate microvascular outcome was 22% (relative risk 0.78, p=0.02) lower in the lifestyle intervention group compared with the metformin group and 21% (relative risk 0.79, p=0.03) lower than in the placebo group. There were no significant differences among the treatment groups in men. The prevalence of microvascular disease in participants who did not develop diabetes was 28% lower than that in those who developed diabetes in a treatment group adjusted model (p<0.0001).
Figure 3 Prevalence of aggregate microvascular complication and individual microvascular components by DPPOS end (2012–2013). Placebo (red solid), metformin (blue dotted pattern), lifestyle (green diagonal stripes). 3A. By treatment group. None of the treatment group differences achieved statistical significance for the aggregate or the microvascular components. The aggregate microvascular is expressed as the average prevalence among the 3 components of nephropathy, retinopathy and neuropathy. 3B. By pre-specified subgroups according to sex and diabetes status. Prevalence was greater in men than in women in each of the three treatment groups. In women, the prevalence of the aggregate microvascular outcome was 22% (relative risk 0.78, p=0.02) lower in the lifestyle intervention group compared with the metformin group and 21% (relative risk 0.79, p=0.03) lower than in the placebo group. There were no significant differences among the treatment groups in men. The prevalence of microvascular disease in participants who did not develop diabetes was 28% lower than that in those who developed diabetes in a treatment group adjusted model (p<0.0001).CC BY-NC-ND · PubMed Central
Figure 4 The role of HbA1c and diabetes duration on microvascular disease and its components were assessed in separate GEE models which included 2 interactions terms for treatment group*glycemia measure and microvascular component*glycemia measure. The interactions of HbA1c with the individual microvascular components were significantly different (p <0.0001). HbA1c (panels a–d) was associated with nephropathy and retinopathy (both p<0.0001) but not neuropathy (p=0.69). The interactions of diabetes duration also differed among the microvascular components (panel e–h) (p=0.01) with longer diabetes duration associated with nephropathy and retinopathy (both p<0.0001) but not with neuropathy (p=0.57). Figure 4A. Aggregate Figure 4B. Nephropathy Figure 4C. Retinopathy Figure 4D. Neuropathy Figure 4E. Aggregate Figure 4F. Nephropathy Figure 4G. Retinopathy Figure 4H. Neuropathy
Figure 4 The role of HbA1c and diabetes duration on microvascular disease and its components were assessed in separate GEE models which included 2 interactions terms for treatment group*glycemia measure and microvascular component*glycemia measure. The interactions of HbA1c with the individual microvascular components were significantly different (p <0.0001). HbA1c (panels a–d) was associated with nephropathy and retinopathy (both p<0.0001) but not neuropathy (p=0.69). The interactions of diabetes duration also differed among the microvascular components (panel e–h) (p=0.01) with longer diabetes duration associated with nephropathy and retinopathy (both p<0.0001) but not with neuropathy (p=0.57). Figure 4A. Aggregate Figure 4B. Nephropathy Figure 4C. Retinopathy Figure 4D. Neuropathy Figure 4E. Aggregate Figure 4F. Nephropathy Figure 4G. Retinopathy Figure 4H. NeuropathyCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 4 Not checked · 57 Own results and interpretations

32 more claims

Create a free account to see all 61 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 21
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. 1991, Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12, Ophthalmology, 83, 823

Cited by

See all 1,029

Metadata

Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2015-11
Volume
3
Issue
11
Pages
866-875
ISSN
2213-8587 (ISSN-L)
OpenAlex
W1891939305
Cited by
1,029
References
34
Citations by year
2026: 71 · 2025: 110 · 2024: 95 · 2023: 124 · 2022: 99 · 2021: 124 · 2020: 104 · 2019: 93 · 2018: 96 · 2017: 69 · 2016: 39 · 2015: 2
FWCI
59.60
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • U.S. Department of Veterans Affairs
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK048339, U01DK048375, U01DK048397, U01DK048406, U01DK048413, DK048489, R01DK078907, U01DK048485, U01DK048400, U01DK048434, U01DK048380, U01DK048412, U01DK048411, U01DK048377, U01DK048437, U01DK048514, U01DK048489, U01DK048468, U01DK048407, U01DK048381, U01DK048443, U01DK048349, U01DK048387, U01DK048404, P30DK017047)
  • National Center for Research Resources (UL1RR025758)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes prevention, lifestyle intervention, metformin, diabetes incidence, microvascular complications, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, long-term follow-up, women, Diabetes Prevention Program Outcomes Study, unmet medical needs, cost-effectiveness
MeSH terms
Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Life Style, Male, Metformin, Middle Aged, Risk Factors, Vascular Diseases, Treatment Outcome, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. https://app.cochat.ai/papers/10.1016/s2213-8587(15)00291-0
The paper
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. (2015). The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(15)00291-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.